Federal Register / Vol. 88, No. 189 / Monday, October 2, 2023 / Notices 67753 

Control and Prevention, has been 

delegated the authority to sign Federal 

Register notices pertaining to 

announcements of meetings and other 

committee management activities, for 

both the Centers for Disease Control and 

Prevention and the Agency for Toxic 

Substances and Disease Registry. 

Kalwant Smagh, 

Director, Office of Strategic Business 

Initiatives, Office of the Chief Operating 

Officer, Centers for Disease Control and 

Prevention. 

[FR Doc. 2023–21566 Filed 9–29–23; 8:45 am] 

BILLING CODE 4163–18–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

[Docket No. CDC–2023–0082] 

Advisory Committee to the Director, 

Centers for Disease Control and 

Prevention 

AGENCY: Centers for Disease Control and 

Prevention (CDC), Department of Health 

and Human Services (HHS). 

ACTION: Notice of meeting and request 

for comment. 

SUMMARY: In accordance with regulatory 

provisions, the Centers for Disease 

Control and Prevention (CDC) 

announces the following meeting of the 

Advisory Committee to the Director, 

Centers for Disease Control and 

Prevention (ACD, CDC). This is a hybrid 

meeting, accessible both in person and 

virtually (webcast live via the World 

Wide Web). It is open to the public and 

limited only by the space available. 

Time will be available for public 

comment. 

DATES: The meeting will be held on 

November 14, 2023, from 9:00 a.m. to 

4:00 p.m., EST (times subject to change). 

Written comments must be received 

on or before October 27, 2023. 

ADDRESSES: 

Meeting address: CDC Roybal 

Campus, Building 19, Auditorium B3, 

1600 Clifton Road NE, Atlanta, Georgia 

30329–4027. 

Please note that the meeting location, 

the CDC Roybal Campus, is a federal 

facility and in-person access is limited 

to United States citizens unless prior 

authorizations, taking up to 30 to 60 

days, have been made. Visitors must 

follow all directions for access to CDC 

facilities. Directions for visitors to CDC, 

including safety requirements related to 

COVID–19; are available at https://

www.cdc.gov/screening/visitors.html. 

Registration: You must register to 

attend this meeting in person. If you 

wish to attend in person, please submit 

a request by email to ACDirector@

cdc.gov or by telephone at (404) 345– 

1039 at least 5 business days in advance 

of the meeting. No registration is 

required to view the meeting via the 

World Wide Web. Information for 

accessing the webcast will be available 

at https://www.cdc.gov/about/advisorycommittee-director/. 

Written comments: You may submit 

comments, identified by Docket No. 

CDC–2023–0082, by either of the 

methods listed below. Do not submit 

comments for the docket by email. CDC 

does not accept comments for the 

docket by email. 

• Federal eRulemaking Portal: 

https://www.regulations.gov. Follow the 

instructions for submitting comments. 

• Mail: Bridget Richards, MPH, 

Centers for Disease Control and 

Prevention, 1600 Clifton Road NE, 

Mailstop H21–10, Atlanta, Georgia 

30329–4027. Attn: Docket No. CDC– 

2023–0082. 

Instructions: All submissions received 

must include the agency name and 

Docket Number. All relevant comments 

received will be posted without change 

to https://www.regulations.gov, 

including any personal information 

provided. For access to the docket to 

read background documents or 

comments received, go to https://

www.regulations.gov. Written comments 

received in advance of the meeting will 

be included in the official record of the 

meeting. 

FOR FURTHER INFORMATION CONTACT: 

Bridget Richards, MPH, Office of the 

Chief of Staff, Centers for Disease 

Control and Prevention, 1600 Clifton 

Road NE, Mailstop H21–10, Atlanta, 

Georgia 30329–4027; Telephone: (404) 

345–1039; Email: ACDirector@cdc.gov. 

SUPPLEMENTARY INFORMATION: 

Purpose: The Advisory Committee to 

the Director, CDC, shall (1) make 

recommendations to the Director 

regarding ways to prioritize the 

activities of the agency in alignment 

with the CDC Strategic Plan required 

under section 305(c); H.R. 2617–1252; 

(2) advise on ways to achieve or 

improve performance metrics in relation 

to the CDC Strategic Plan, and other 

relevant metrics, as appropriate; (3) 

provide advice and recommendations 

on the development of the Strategic 

Plan, and any subsequent updates, as 

appropriate; (4) advise on grant, 

cooperative agreements, contracts, or 

other transactions, as applicable; (5) 

provide other advice to the Director, as 

requested, to fulfill duties under 

sections 301 and 311; and (6) appoint 

subcommittees. The Committee 

recommends ways to prioritize CDC’s 

activities, improve results, and address 

health disparities. It also provides 

guidance to help CDC work more 

effectively with its various private and 

public sector constituents to make 

health protection a practical reality. 

Matters to be Considered: The agenda 

will include an introduction of the new 

CDC Director, Dr. Mandy Cohen, and a 

discussion regarding agency updates 

and priorities. The agenda also includes 

updates on the progress made to date on 

the health equity, laboratory, and data 

and surveillance recommendation; 

discussion and vote on the Laboratory 

Workgroup final recommendations; and 

discussion and votes to sunset the 

Health Equity and Laboratory 

workgroups due to completion of their 

terms of reference. CDC’s Senior 

Advisor for Health Strategy will present 

on supporting healthy families, and a 

Senior Counselor to the CDC Director 

will present on COVID–19 recission. 

Agenda items are subject to change as 

priorities dictate. 

Public Participation 

Interested persons or organizations 

are invited to participate by submitting 

written views, recommendations, and 

data. Please note that comments 

received, including attachments and 

other supporting materials, are part of 

the public record and are subject to 

public disclosure. Comments will be 

posted on https://www.regulations.gov. 

Therefore, do not include any 

information in your comment or 

supporting materials that you consider 

confidential or inappropriate for public 

disclosure. If you include your name, 

contact information, or other 

information that identifies you in the 

body of your comments, that 

information will be on public display. 

CDC will review all submissions and 

may choose to redact, or withhold, 

submissions containing private or 

proprietary information such as Social 

Security numbers, medical information, 

inappropriate language, or duplicate/ 

near duplicate examples of a mass-mail 

campaign. CDC will carefully consider 

all comments submitted into the docket. 

Written Public Comment: The docket 

will be opened to receive written 

comments on October 2, 2023 through 

October 27, 2023. 

The Director, Office of Strategic 

Business Initiatives, Office of the Chief 

Operating Officer, Centers for Disease 

Control and Prevention, has been 

delegated the authority to sign Federal 

Register notices pertaining to 

announcements of meetings and other 


lotter on DSK11XQN23PROD with NOTICES1
67754 Federal Register / Vol. 88, No. 189 / Monday, October 2, 2023 / Notices 

committee management activities, for 

both the Centers for Disease Control and 

Prevention and the Agency for Toxic 

Substances and Disease Registry. 

Kalwant Smagh, 

Director, Office of Strategic Business 

Initiatives, Office of the Chief Operating 

Officer, Centers for Disease Control and 

Prevention. 

[FR Doc. 2023–21567 Filed 9–29–23; 8:45 am] 

BILLING CODE 4163–18–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

[Docket No. CDC–2023–0080] 

Guidelines for the Use of Doxycycline 

Post-Exposure Prophylaxis for 

Bacterial Sexually Transmitted 

Infection (STI) Prevention; Request for 

Comment and Informational 

Presentation 

AGENCY: Centers for Disease Control and 

Prevention (CDC), Department of Health 

and Human Services (HHS). 

ACTION: Notice with comment period. 

SUMMARY: The Centers for Disease 

Control and Prevention (CDC) in the 

Department of Health and Human 

Services (HHS) announces the opening 

of a docket to obtain comment on 

proposed guidelines for the use of 

doxycycline post-exposure prophylaxis 

(PEP) for prevention of bacterial 

sexually transmitted infections (STI). 

The proposed guidelines for bacterial 

STI prevention include post-exposure 

prophylaxis with doxycycline 

(doxycycline PEP) because it has 

demonstrated benefit in reducing 

chlamydia, gonorrhea, and syphilis 

infections and represents a new 

approach to addressing STI prevention 

in populations at increased risk for 

these infections. Doxycycline PEP, 

when offered, should be implemented 

in the context of a comprehensive 

sexual health approach including risk 

reduction counseling, STI screening and 

treatment, recommended vaccination, 

and linkage to HIV pre-exposure 

prophylaxis (PrEP), HIV care, or other 

services, as appropriate. The purpose of 

the proposed guidelines is to provide 

updated clinical guidance for healthcare 

providers to inform the use of 

doxycycline PEP for preventing 

bacterial STI infections. CDC has made 

available a pre-recorded informational 

presentation to provide information 

about the studies considered when 

developing the proposed guideline, 

explain the public comment process, 

and provide an overview of important 

monitoring for antibiotic use and 

antibiotic resistance that the agency will 

be considering to address potential 

risks. 

DATES: Written comments must be 

received on or before November 16, 

2023. An Informational Presentation has 

been pre-recorded and is available at 

https://npin.cdc.gov/. 

ADDRESSES: You may submit comments, 

identified by Docket No. CDC–2023– 

0080 by either of the methods listed 

below. Do not submit comments by 

email. CDC does not accept comments 

by email. 

• Federal eRulemaking Portal: http:// 

www.regulations.gov. Follow the 

instructions for submitting comments. 

• Mail: [Division of STD Prevention, 

Centers for Disease Control and 

Prevention, 1600 Clifton Road NE, 

Mailstop US12–2, Atlanta, GA 30329, 

Attn: Docket No. CDC–2023–0080]. 

Instructions: All submissions received 

must include the agency name and 

Docket Number. All relevant comments 

received will be posted without change 

to http://regulations.gov, including any 

personal information provided. For 

access to the docket to read background 

documents or comments received, go to 

http://www.regulations.gov. 

The informational presentation can be 

accessed at https://npin.cdc.gov/. 

FOR FURTHER INFORMATION CONTACT: John 

R. Papp, Centers for Disease Control and 

Prevention, 1600 Clifton Road NE, 

Mailstop U12–3, Atlanta, GA 30329; 

Telephone: 404–639–8000; Email: 

jwp6@cdc.gov. 

SUPPLEMENTARY INFORMATION: CDC’s 

proposed guidelines for the use of postexposure prophylaxis with doxycycline 

for bacterial STI prevention in the 

United States is available under the 

Supporting and Related Materials tab in 

the docket for this notice, Docket No. 

CDC–2023–0080, on http://

www.regulations.gov. 

Public Participation 

Interested persons or organizations 

are invited to participate by submitting 

written views, recommendations, and 

data. In addition, CDC invites comments 

specifically on the following questions 

proposed in this Notice: 

• Based on the evidence presented in 

the full guidelines document (see the 

Supporting and Related Materials tab in 

the docket), does the evidence support 

the proposed guidelines for the use of 

post-exposure prophylaxis with 

doxycycline for bacterial STI 

prevention, including but not limited to 

risks and benefits? If not, please state 

the reason why and, if available, 

provide additional evidence for 

consideration. 

• Are CDC’s proposed guidelines for 

the use of post-exposure prophylaxis 

with doxycycline bacterial STI 

prevention clearly written? If not, what 

changes do you propose to make it 

clear? 

• If implemented as currently drafted, 

do you believe the proposed guidelines 

for the use of post-exposure prophylaxis 

with doxycycline for bacterial STI 

prevention would result in improved 

prevention of bacterial STIs in the 

United States? If not, please provide an 

explanation and supporting data or 

evidence. 

• How can these proposed guidelines 

most effectively reach and be received 

by populations who would benefit from 

this intervention? 

Please note that comments received, 

including attachments and other 

supporting materials, are part of the 

public record and are subject to public 

disclosure. Comments will be posted on 

https://www.regulations.gov. Therefore, 

do not include any information in your 

comment or supporting materials that 

you consider confidential or 

inappropriate for public disclosure. If 

you include your name, contact 

information, or other information that 

identifies you in the body of your 

comments, that information will be on 

public display. CDC will review all 

submissions and may choose to redact, 

or withhold, submissions containing 

private or proprietary information such 

as Social Security numbers, medical 

information, inappropriate language, or 

duplicate/near duplicate examples of a 

mass-mail campaign. 

Background 

Incidence of sexually transmitted 

infections (STIs) caused by Neisseria 

gonorrhoeae (causative agent of 

gonorrhea), Chlamydia trachomatis 

(causative agent of chlamydia), and 

Treponema pallidum (causative agent of 

syphilis) continues to increase in the 

United States. Novel approaches are 

needed to address the STI epidemic, 

especially for populations 

disproportionately affected (1). Postexposure prophylaxis (PEP) involves 

taking a medication to prevent an 

infection after a possible exposure and 

is a common strategy for prevention of 

HIV and other infections. PEP is a form 

of chemoprophylaxis and distinct from 

pre-exposure prophylaxis (PrEP) which 

involves taking a medication before 

exposure occurs. Doxycycline, a broadspectrum tetracycline antibiotic, is used 

as pre- or post-exposure prophylaxis to 

prevent infections such as malaria and 

Lyme disease (2). Doxycycline is well 


lotter on DSK11XQN23PROD with NOTICES1